NXT USA has announced positive results using its proprietary formulation, Digexin, on various types of gastrointestinal (GI) upset in adults using GLP-1 receptor agonist therapy.
The open-label study included patients who had been taking oral semaglutide (the generic name for GLP-1 drugs such as Ozempic or Rybelsus) for several months and were experiencing various GI side effects.
During three weeks, these subjects were supplemented with Digexin and were monitored for changes in GI comfort and overall well-being.
Participants reported meaningful improvements in digestive comfort and function, including reductions in constipation, reflux and swallowing difficulties, along with more regular and complete bowel movements.
At least half of GLP-1 patients experience GI side effects, with some cases so worrisome that drug makers are facing class-action lawsuits about digestive contraindications.
Beyond digestive outcomes, subjects taking Digexin also experienced improvements in sleep quality, reduced perceived stress and greater overall quality of life.
Importantly, Digexin was well tolerated and no adverse events were reported.
“These results demonstrate Digexin’s potential to complement GLP-1 therapies by reducing common side effects and supporting overall well-being,” said Eric Anderson, Managing Director of NXT-USA.
“As GLP-1 use grows worldwide, there is a clear need for supportive solutions that enhance patient comfort and compliance. Digexin’s bidirectional action on the gut and brain makes it uniquely suited to this role.”
Introducing GLP-2
The supplement industry has capitalised on the GLP-1 craze by launching auxiliary products for people on GLP-1 drugs.
Some such supplements suggest modulating GLP-1 levels in the same way the pharmaceutical does, but whilst some ingredients do work on the GLP-1 pathway, no supplement comes close to the results found with semaglutide.
However, a legitimate space for supplements remains for helping patients manage side effects from the drug, in particular, GI distress.
Even here, rare is the ingredient that has been clinically validated on actual GLP-1 patients.
“We are not about activating GLP-1 activity,” said Anderson. “Digexin addresses GLP-2 — as in no. 2."
"That is, constipation that results from dieting strategies. Our research is built on rigorous, reproducible human clinical trials designed for real-world application."
"Digexin delivers results that consumers can trust and brands can build on.”
Digexin features a proprietary blend of okra fruit (Abelmoschus esculentus) and winter cherry root (Withania somnifera).
Together, these botanicals support gut health through complementary mechanisms.
Okra’s soothing polysaccharides coat and hydrate the intestinal lining, promoting smoother transit, whilst winter cherry root helps the body recalibrate stress responses by reducing cortisol and supporting serotonin production.
This dual action targets the interplay between stress and digestion, helping normalise bowel rhythms, reduce discomfort and restore balance in as little as seven days.
“In my 30 years in this industry, I have never received so much unsolicited feedback about a supplement,” continued Anderson.
“When we share Digexin with friends, family and business partners, people come back — often unprompted — to say it has changed their lives."
"No one likes to talk about digestive issues, yet people feel compelled to share how much better they feel. That kind of response speaks volumes about the difference Digexin can make.”
The preliminary findings, which are being submitted for peer-review publication, highlight the potential for nutraceutical solutions to complement existing approaches to digestive health, weight management and metabolic wellness.
The study builds upon the existing clinical dossier for Digexin, which includes two published human clinical studies, one in January 2024 and the second in May 2024.
These trials demonstrated consistent and significant improvements in digestive outcomes such as gas, bloating, transit time and daily bowel movements.
They also showed reductions in stress and improvements in sleep and quality of life.
Biomarker analyses revealed increases in serotonin and reductions in cortisol, along with favourable changes to other gut and immune markers.
Together, these findings suggest that Digexin supports healthy gut-brain communication whilst promoting digestive comfort and overall wellbeing.
The new study results indicate the benefits seen in the first two Digexin studies could translate into benefits in this specific population.